Showing 1531-1540 of 2050 results for "".
- New Contact Lens Update Focuses on Ocular Allergyhttps://modernod.com/news/new-contact-lens-update-focuses-on-ocular-allergy/2479141/The Centre for Ocular Research & Education (CORE) has published issue number 59 of its free online education magazine,
- Lantronix Contributes to eSight Design, Enabling Individuals With Serious Visual Impairment to Seehttps://modernod.com/news/lantronix-contributes-to-esight-design-enabling-individuals-with-serious-visual-impairment-to-see/2479082/Lantronix announced that its engineering services team supported eSight Corp. in the development of an enhanced vision device that enables individuals with serious visual impairment to see. eSight was recently recognized as a manufacturer of the Best Wearable/Healthcare Hardware/Soft
- EMA’s Blood Clot Review Exonerates AstraZeneca COVID-19 Vaccine, But Monitoring Continueshttps://modernod.com/news/emas-blood-clot-review-exonerates-astrazeneca-covid-19-vaccine-but-monitoring-continues/2478990/The European Medicines Agency (EMA) on Thursday said a review by its Pharmacovigilance Risk Assessment Committee (PRAC) has determined that AstraZeneca’s COVID-19 vaccine AZD1222 is safe and effective at preventing COVID-19, and that its benefits are “far greater” than any poten
- Retina Consultants of America Continues Growth With Partnership in Kansas and Missourihttps://modernod.com/news/retina-consultants-of-america-continues-growth-with-partnership-in-kansas-and-missouri/2478935/Retina Consultants of America (RCA) announced it has added Retina Associates, P.A. of Kansas City, based in Kansas and Missouri, to its group of practices. Retina Associates, P.A. serves the greater Kansas City, Topeka, Sedalia, and surrounding areas. Terms of the deal were no
- New Survey Assessment Finds Debilitating Impact of Thyroid Eye Disease (TED) on Quality of Life Continues Beyond Acute Disease into Chronic Phasehttps://modernod.com/news/new-survey-assessment-finds-debilitating-impact-of-thyroid-eye-disease-ted-on-quality-of-life-continues-beyond-acute-disease-into-chronic-phase/2478913/Horizon Therapeutics announced results of a new Thyroid Eye Disease (TED) quality of life assessment presented at the North American Neuro-Ophthalmology Society (NANOS) 2021 Virtual Annual Meeting. Findings demonstrate that TED not only has a significant burden on patients during the acute (activ
- UK Officials Defend Contingency Plan to Mix COVID-19 Vaccines in Rare Caseshttps://modernod.com/news/uk-officials-defend-contingency-plan-to-mix-covid-19-vaccines-in-rare-cases/2478710/According to a guidance update on December 31, the UK government will allow people to be given doses of different COVID-19 vaccines under certain circumstances, despite a lack of evidence about the extent of immunity offered by such mixing. The issue has sparked criticism after a report in Th
- Kubota Vision Provides Update on Kubota Glasses—Wearable Device for Myopia Controlhttps://modernod.com/news/kubota-vision-provides-update-on-kubota-glasses-wearable-device-for-myopia-control/2478680/Kubota Vision announced that the company achieved a milestone by completing a first spectacle-style wearable prototype based on Kubota Glasses technology. Kubota Vision conducted a clinical study in early 2020 with an electronic tabletop optical projection device that embodied Kubota Glass
- Influx of New Contact Lens Patients Calls for Simplified Wear-and-Care Educationhttps://modernod.com/news/influx-of-new-contact-lens-patients-calls-for-simplified-wear-and-care-education/2478671/Within days of mask guidelines being implemented earlier this year, the reports of fogging started streaming in from glasses and sunglasses wearers. Social feeds were soon packed with photos of the annoying condensation and news reports began offering tips on how to avoid condensation. In 2020, t
- CMS Confirms Continued Separate Payment for Omeros’ Omidria in Ambulatory Surgery Centershttps://modernod.com/news/cms-confirms-continued-separate-payment-for-omeros-fda-approved-omidria-in-ambulatory-surgery-centers/2478625/Omeros announced that the Centers for Medicare & Medicaid Services (CMS) confirmed separate payment in ambulatory surgery centers (ASCs) for Omeros’ cataract surgery drug Omidria (phenylephrine and ketorolac intraocular solution) 1%/0.3%. In its final rule directed to the Medicare outpatient
- Late-Breaking 12-Month Data of Investigational RPGR Gene Therapy Shows Statistically Significant and Continued Vision Improvement in Patients with XLRPhttps://modernod.com/news/late-breaking-12-month-data-of-investigational-rpgr-gene-therapy-shows-statistically-significant-and-continued-vision-improvement-in-patients-with-xlrp/2478557/The Janssen Pharmaceutical Companies of Johnson & Johnson announced new 12-month data from the ongoing phase 1/2 trial (